中国执业药师
中國執業藥師
중국집업약사
China Licensed Pharmacist
2015年
10期
23-26
,共4页
儿科%支气管肺炎%成本-效果比%青霉素类抗生素
兒科%支氣管肺炎%成本-效果比%青黴素類抗生素
인과%지기관폐염%성본-효과비%청매소류항생소
Pediatrics%Bronchial Pneumonia%Cost-effectiveness Ratio%Penicillins Antibiotics
目的：研究不同药物治疗方案对儿科常见病支气管肺炎产生的成本-效果比，寻找最合理的临床路径。方法：在我院2014年儿科住院病例中选取支气管肺炎患者共281例，随机分成3组，分别给予注射用青霉素钠、注射用阿莫西林钠-克拉维酸钾、注射用哌拉西林钠-他唑巴坦钠3种药物进行抗菌治疗，运用药物经济学原理对治疗方案进行评价。结果：注射用青霉素钠成本-效果比率为4846.63～4877.30元/例；注射用阿莫西林钠-克拉维酸钾的成本-效果比率为1985.79元/例；注射用哌拉西林钠-他唑巴坦钠的成本-效果比率为2548.10元/例。增量分析得到注射用阿莫西林钠-克拉维酸钾相对于注射用青霉素钠为绝对优势方案；注射用哌拉西林钠-他唑巴坦钠相对于注射用青霉素钠增量成本-效果比为319.18～345.53元；注射用哌拉西林钠-他唑巴坦钠相对于注射用阿莫西林钠-克拉维酸钾增量成本-效果比为9905.63元。结论：通过研究得到注射用阿莫西林钠-克拉维酸钾是对儿科支气管肺炎进行抗菌治疗的优选方案，花费较低的治疗成本可得到较好的治疗效果，为最合理的临床路径。
目的：研究不同藥物治療方案對兒科常見病支氣管肺炎產生的成本-效果比，尋找最閤理的臨床路徑。方法：在我院2014年兒科住院病例中選取支氣管肺炎患者共281例，隨機分成3組，分彆給予註射用青黴素鈉、註射用阿莫西林鈉-剋拉維痠鉀、註射用哌拉西林鈉-他唑巴坦鈉3種藥物進行抗菌治療，運用藥物經濟學原理對治療方案進行評價。結果：註射用青黴素鈉成本-效果比率為4846.63～4877.30元/例；註射用阿莫西林鈉-剋拉維痠鉀的成本-效果比率為1985.79元/例；註射用哌拉西林鈉-他唑巴坦鈉的成本-效果比率為2548.10元/例。增量分析得到註射用阿莫西林鈉-剋拉維痠鉀相對于註射用青黴素鈉為絕對優勢方案；註射用哌拉西林鈉-他唑巴坦鈉相對于註射用青黴素鈉增量成本-效果比為319.18～345.53元；註射用哌拉西林鈉-他唑巴坦鈉相對于註射用阿莫西林鈉-剋拉維痠鉀增量成本-效果比為9905.63元。結論：通過研究得到註射用阿莫西林鈉-剋拉維痠鉀是對兒科支氣管肺炎進行抗菌治療的優選方案，花費較低的治療成本可得到較好的治療效果，為最閤理的臨床路徑。
목적：연구불동약물치료방안대인과상견병지기관폐염산생적성본-효과비，심조최합리적림상로경。방법：재아원2014년인과주원병례중선취지기관폐염환자공281례，수궤분성3조，분별급여주사용청매소납、주사용아막서림납-극랍유산갑、주사용고랍서림납-타서파탄납3충약물진행항균치료，운용약물경제학원리대치료방안진행평개。결과：주사용청매소납성본-효과비솔위4846.63～4877.30원/례；주사용아막서림납-극랍유산갑적성본-효과비솔위1985.79원/례；주사용고랍서림납-타서파탄납적성본-효과비솔위2548.10원/례。증량분석득도주사용아막서림납-극랍유산갑상대우주사용청매소납위절대우세방안；주사용고랍서림납-타서파탄납상대우주사용청매소납증량성본-효과비위319.18～345.53원；주사용고랍서림납-타서파탄납상대우주사용아막서림납-극랍유산갑증량성본-효과비위9905.63원。결론：통과연구득도주사용아막서림납-극랍유산갑시대인과지기관폐염진행항균치료적우선방안，화비교저적치료성본가득도교호적치료효과，위최합리적림상로경。
Objective: To study the cost-effectiveness ratio of the treatment of bronchial pneumonia as a common disease in pediatrics with different therapeutic regimens and to find out the most reasonable clinical pathway. Methods: About 281 patients with bronchial pneumonia were chosen from hospitalized patients of pediatrics in our hospital in 2014. They were randomly divided into 3 groups, each group was given penicillin sodium for injection, amoxilinna and clavulanate potassium for injection and piperacillin sodium and tazobactam sodium for injection respectively for antimicrobial therapy and the assessment was made on therapeutic schemes according to the principle of pharmacoeconomics. Results: The cost-effectiveness ratio of penicillin sodium for injection, amoxicillin sodium and clavulanate potassium for injection and piperacillin sodium and tazobactam sodium for injection was 4 846.63 ~4 877.30, 1 985.79 and 2 548.10 yuan/each respectively. The incremental analysis showed that the therapeutic scheme with amoxicillin sodium and clavulanate potassium for injection had an obvious advantage as opposed to piperacillin sodium for injection, the incremental cost-effectiveness ratio of piperacillin sodium and tazobactam sodium for injection was 319.18 ~ 345.53 as opposed to penicillin sodium for injection and 9 905.63 as opposed to amoxilinna and clavulanate potassium for injection. Conclusion: The results showed the using amoxilinna and clavulanate potassium for injection is an optimal therapeutic scheme for antimicrobial treatment of pediatric bronchial pneumonia, with lower treatment cost and better effectiveness. It can be regarded as the most reasonable clinical pathway.
